Liabilities and Equity of RVL Pharmaceuticals plc from 31 Dec 2017 to 30 Jun 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
RVL Pharmaceuticals plc quarterly Liabilities and Equity in USD history and change rate from 31 Dec 2017 to 30 Jun 2023.
  • RVL Pharmaceuticals plc Liabilities and Equity for the quarter ending 30 Jun 2023 was $85,404,000, a 32% decline year-over-year.
Source SEC data
View on sec.gov
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

RVL Pharmaceuticals plc Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $85,404,000 -$39,426,000 -32% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $111,108,000 -$33,200,000 -23% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $128,510,000 -$16,160,000 -11% 31 Dec 2022 10-Q 14 Aug 2023 2023 Q2
Q3 2022 $155,355,000 +$45,808,000 +42% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $124,830,000 -$210,181,000 -63% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $144,308,000 -$210,860,000 -59% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $144,670,000 -$226,279,000 -61% 31 Dec 2021 10-K 20 Mar 2023 2022 FY
Q3 2021 $109,547,000 -$317,699,000 -74% 30 Sep 2021 10-Q 15 Nov 2021 2021 Q3
Q2 2021 $335,011,000 -$127,686,000 -28% 30 Jun 2021 10-Q 16 Aug 2021 2021 Q2
Q1 2021 $355,168,000 -$119,966,000 -25% 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $370,949,000 -$92,306,000 -20% 31 Dec 2020 10-K 30 Mar 2022 2021 FY
Q3 2020 $427,246,000 -$66,927,194 -14% 30 Sep 2020 10-Q 10 Nov 2020 2020 Q3
Q2 2020 $462,697,000 -$181,084,000 -28% 30 Jun 2020 10-Q 11 Aug 2020 2020 Q2
Q1 2020 $475,134,000 -$300,743,000 -39% 31 Mar 2020 10-Q 12 May 2020 2020 Q1
Q4 2019 $463,255,000 -$332,369,000 -42% 31 Dec 2019 8-K 08 Sep 2021
Q3 2019 $494,173,194 -$400,743,926 -45% 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $643,781,000 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $775,877,000 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q4 2018 $795,624,000 -$123,889,625 -13% 31 Dec 2018 10-K 19 Mar 2020 2019 FY
Q3 2018 $894,917,120 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q4 2017 $919,513,625 31 Dec 2017 8-K 20 Dec 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.